Allegria Therapeutics AG
Therapeutics that modulate mast cell activity
Allegria Therapeutics is a Basel-based biopharma startup established in 2023 with a commitment to build a differentiated portfolio of therapeutic approaches around biological targets that modulate mast cells as drivers of allergy and inflammatory disease. We focus our efforts on sustainable innovation to address significant unmet medical need and drive long-term growth.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
12.12.2025
Allegria Therapeutics secures USD 5.1 million Seed extension financing (venturelab.swiss)
21.05.2024
Venture Leaders Biotech scale new heights in Boston (venturelab.swiss)
13.05.2024
Allegria Therapeutics secures USD 3.5 million Seed Financing to drive innovation in mast cell-mediated disease treatment (venturelab.swiss)
03.05.2024
Allegria Therapeutics: The Venture Leader Biotech modulating mast cell activity (venturelab.swiss)
23.04.2024
The road to Boston: Venture Leaders Biotech 2024 kick-off their roadshow at Swiss Biotech Day (venturelab.swiss)
No milestones
No Jobs
No videos and documents
Venture Leaders Biotech
Allegria Therapeutics AG
Therapeutics that modulate mast cell activity
Website:
www.allegriatx.com
Headquarter:
Basel
Foundation Date:
December 2023
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
- Inflammation
Support received
